Climb Real Estate, a boutique San Francisco brokerage focused on city-dwelling Millennials, has been acquired by NRT LLC, the nation’s largest residential brokerage, the companies announced Wednesday.NRT is the parent of Coldwell Banker, Sotheby’s International Realty and ZipRealty and a subsidiary of Realogy, a publicly traded real estate conglomerate.NRT has pursued the same approach with other regional firms it acquired including the Corcoran Group in New York City and Laura McCarthy Real Estate in St. Louis, said Bruce Zipf, NRT’s president and chief executive.Climb tries hard to appeal to Millennials by focusing on mobile technology and social media.“I believe what this represents is a more traditional type platform coming together with a more innovative, unique-type platform” and providing the financial capital to expand Climb in the Bay Area, Zipf said.Greg Macres, NRT’s executive vice president for the western region, said, We want our agents to be more mobile (and) stretch the boundaries of technology.
NYS Entity Status
NYS Filing Date
MARCH 12, 2014
NYS DOS ID#
NYS Entity Type
DOMESTIC LIMITED LIABILITY COMPANY
2014 - INNOVATIVE CLINICAL REALTY LLC
Around the Web
- Nation’s largest brokerage firm acquires SF’s Climb Real Estate
By Kathleen Pender - Wednesday Aug 31, 2016
- The Top 10 Moments of New York Fashion Week
By THE NEW YORK TIMES - Friday Sep 15, 2017
Highlights from the shows, including a celebrity-packed front row at Calvin Klein and a trek to Bedford Hills, N.Y., to see Ralph Lauren’s vintage cars.
- Women of Sex Tech, Unite
By ANNA NORTH - Friday Aug 18, 2017
New York is becoming a cultural center for young women trying to disrupt the male-dominated industries of design engineering and sex toys.
- By Design: The New Wave in Floral Arrangements
By LINDSAY TALBOT - Thursday Aug 31, 2017
For the most innovative designers working today, form is just as important as flora.
- The New Health Care: Can the U.S. Repair Its Health Care While Keeping Its Innovation Edge?
By AARON E. CARROLL and AUSTIN FRAKT - Monday Oct 9, 2017
The two are not mutually exclusive, but harm to innovation in America could harm other nations, too.
- FDA Refuses to Review Acorda Parkinson’s Drug, Shares Tumble
By Ben Fidler - Tuesday Aug 29, 2017
The heat is on Acorda Therapeutics once again. Months after Acorda lost a key group of patents, the FDA has declined to review, at least for now, an experimental Parkinson’s disease drug that is critical to the company’s future. Acorda (NASDAQ: ACOR) said this morning that the FDA has sent the Ardsley, NY, company a […]